<DOC>
	<DOCNO>NCT00266136</DOCNO>
	<brief_summary>The study patient primary secondary AML high-risk MDS use risk-stratified , randomized design evaluate role high-dose araC induction , G-CSF priming , autologous stem cell transplantation .</brief_summary>
	<brief_title>Biology Treatment Strategy AML Its Subgroups : Multicenter Randomized Trial German Acute Myeloid Leukemia Cooperative Group ( AMLCG )</brief_title>
	<detailed_description>The present study German AML Cooperative Group design order investigate effect AML typical therapeutic strategy AML related disease . Thus , entry criterion age start 16 year upper age limit , de novo AML AML secondary chemotherapy radiotherapy another disease myelodysplasia subtype RAEB bone marrow blast great 10 % . All randomization stratify accord karyotype favorable / intermediate / unfavorable . Additional stratification accord LDH &lt; / &gt; = 700 U age &lt; / &gt; = 60 Y . Standard treatment ( A ) double induction TAD HAM , consolidation TAD maintenance treatment monthly AD-AT-AC-AT - , rotatingly . Experimental modification compare stan-dard treatment ( B ) double induction HAM-HAM , ( C ) multiple course G-CSF chemotherapy course ( D ) instead maintenance treatment myeloablative consolidation Bu/Cy autologous blood stem cell transplantation . Intent treat condition guarantee randomization induction treatment start . In order evaluate effect every single modification randomization ( C ) equally distributed patient treatment arm ( A ) ( B ) also true randomization ( D ) ( balance randomization ) . Similarly balanced treatment arm patient accord diagnosis , age risk factor like serum LDH karyotype . In order adapt treatment intensity age patient 60 year older receive second induction course case 5 % residual bone marrow blast . In addition , AraC dose HAM reduce 1 instead 3 g/sqm age group . Furthermore , treatment arm include stem cell transplantation patient 60+ year . Pri-mary endpoint compare therapeutic strategy event-free survival treatment start ( A , B , C ) achievement remission ( D ) , respectively . By design AMLCG 2000 trial contribute relevant experience optimum therapeutic strategy biological subgroup de novo AML , secondary AML MDS . Furthermore , new biological subgroup significance relate treatment strategy define .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>Acute myeloid leukemia ( denovo AML , secondary AML , highrisk MDS ) Age 16 upper age limit Written inform consent Severe comorbidity Presence malignancy Prior antileukemic treatment Pregnancy Severe psychiatric disorder circumstance may compromise cooperation patient</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>AML treatment , de-novo , secondary , high-risk MDS , chemotherapy , autologous SCT , adult</keyword>
</DOC>